Mavacamten在转诊室间隔减容术的肥厚型心肌病患者中的56周结果:VALOR-HCM随机临床试验
VALOR-HCM试验纳入112例有严重症状的梗阻性肥厚型心肌病患者(NYHA III/IV级)且转诊室间隔减容术,随机接受Mavacamten或安慰剂(16周后交叉),第56周时Mavacamten组复合终点(需SRT、符合指南SRT资格或不可评估)发生率为8.9%,安慰剂交叉组为19.2%,LVOT压差和症状持续改善,但部分患者出现LVEF下降需密切监测。
要点
- Mavacamten可降低转诊SRT的梗阻性HCM患者第56周复合终点发生率
- LVOT压差和NYHA心功能分级持续改善
- LVEF<50%发生率11.1%,需密切监测左室收缩功能
核心结论
- 在有症状的梗阻性HCM患者中,Mavacamten减少第56周时对SRT的需求,并持续改善LVOT压差和症状。
- 鉴于左室收缩功能不全的潜在风险,仍需密切监测。
研究设计与样本
- 双盲、安慰剂对照、多中心随机临床试验,16周时安慰剂交叉,2020年7月至2022年11月从19家美国HCM中心招募。
- 纳入112例梗阻性HCM(NYHA III/IV级)转诊SRT患者,108例符合第56周评估(平均年龄60.3岁,男性54例[50.0%])。
- Mavacamten组从基线持续用药56周,安慰剂组从第16周交叉至第56周(40周暴露),根据超声LVOT压差和LVEF滴定剂量。
主要发现
- 第56周,原Mavacamten组5/56例(8.9%)达到复合终点(3例接受SRT,1例符合SRT资格,1例不可评估),安慰剂交叉组10/52例(19.2%)达到复合终点(3例接受SRT,4例符合SRT资格,3例不可评估)。
- 96/108例(89%)长期继续Mavacamten治疗。
- 第56周时,Mavacamten组和安慰剂交叉组静息LVOT压差分别持续降低34.0 mmHg(95%CI -43.5至-24.5)和33.2 mmHg(95%CI -41.9至-24.5),Valsalva LVOT压差分别降低45.6 mmHg(95%CI -56.5至-34.6)和54.6 mmHg(95%CI -66.0至-43.3)。
- NYHA分级改善≥1级在原Mavacamten组为51/55例(93%),安慰剂交叉组为37/51例(73%)。
- 12/108例(11.1%;95%CI 5.87%-18.60%)出现LVEF<50%(原Mavacamten组7/56例[12.5%],安慰剂交叉组5/52例[9.6%]),其中2例LVEF≤30%,1例死亡,12例中9例(75%)继续治疗。
临床怎么用
- 对于有严重症状的梗阻性HCM且转诊SRT的患者,Mavacamten可作为减少SRT需求的治疗选择。
- 使用Mavacamten期间需根据超声LVOT压差和LVEF滴定剂量,并密切监测左室收缩功能。
局限性
- 样本量较小(108例可评估),可能影响结果的精确性。
- 安慰剂交叉设计可能影响长期比较的解读。
- 未报告长期临床硬终点(如死亡率、心衰住院)的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus reduce the short-term need for septal reduction therapy (SRT). OBJECTIVE: To examine the cumulative longer-term effect of mavacamten on the need for SRT through week 56. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled, multicenter, randomized clinical trial with placebo crossover at 16 weeks, conducted from July 2020 to November 2022. Participants were recruited from 19 US HCM centers. Included in the trial were patients with obstructive HCM (New York Heart Association class III/IV) referred for SRT. Study data were analyzed April to August 2023. INTERVENTIONS: Patients initially assigned to mavacamten at baseline continued the drug for 56 weeks, and patients taking placebo crossed over to mavacamten from week 16 to week 56 (40-week exposure). Dose titrations were performed using echocardiographic LVOT gradient and LV ejection fraction (LVEF) measurements. MAIN OUTCOME AND MEASURE: Proportion of patients undergoing SRT, remaining guideline eligible or unevaluable SRT status at week 56. RESULTS: Of 112 patients with highly symptomatic obstructive HCM, 108 (mean [SD] age, 60.3 [12.5] years; 54 male [50.0%]) qualified for the week 56 evaluation. At week 56, 5 of 56 patients (8.9%) in the original mavacamten group (3 underwent SRT, 1 was SRT eligible, and 1 was not SRT evaluable) and 10 of 52 patients (19.2%) in the placebo crossover group (3 underwent SRT, 4 were SRT eligible, and 3 were not SRT evaluable) met the composite end point. A total of 96 of 108 patients (89%) continued mavacamten long term. Between the mavacamten and placebo-to-mavacamten groups, respectively, after 56 weeks, there was a sustained reduction in resting (mean difference, -34.0 mm Hg; 95% CI, -43.5 to -24.5 mm Hg and -33.2 mm Hg; 95% CI, -41.9 to -24.5 mm Hg) and Valsalva (mean difference, -45.6 mm Hg; 95% CI, -56.5 to -34.6 mm Hg and -54.6 mm Hg; 95% CI, -66.0 to -43.3 mm Hg) LVOT gradients. Similarly, there was an improvement in NYHA class of 1 or higher in 51 of 55 patients (93%) in the original mavacamten group and in 37 of 51 patients (73%) in the placebo crossover group. Overall, 12 of 108 patients (11.1%; 95% CI, 5.87%-18.60%), which represents 7 of 56 patients (12.5%) in the original mavacamten group and 5 of 52 patients (9.6%) in the placebo crossover group, had an LVEF less than 50% (2 with LVEF ≤30%, one of whom died), and 9 of 12 patients (75%) continued treatment. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that in patients with symptomatic obstructive HCM, mavacamten reduced the need for SRT at week 56, with sustained improvements in LVOT gradients and symptoms. Although this represents a useful therapeutic option, given the potential risk of LV systolic dysfunction, there is a continued need for close monitoring. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04349072.
引用
- Desai MY, Owens A, Wolski K, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37639243. doi:10.1001/jamacardio.2023.3342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。